Document:

GENVEC,
INC.

    

    Form
of Warrant To Purchase Common Stock

    

    Warrant
No.: 2010-__

    Number of
Shares of Common Stock:

    Date of
Issuance: ________________, 2010 (“Issuance Date”)

    

    GenVec,
Inc., a Delaware Corporation, (the “Company”), hereby certifies
that, for good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, ______________________, the registered holder hereof or
its permitted assigns (the “Holder”), is entitled, subject
to the terms set forth below, to purchase from the Company, at the Exercise
Price (as defined below) then in effect, upon surrender of this Warrant to
Purchase Common Stock (including any Warrants to Purchase Common Stock issued in
exchange, transfer or replacement hereof, the “Warrant”), at any time or
times on or after the Issuance Date, but not after 11:59 p.m., New York Time, on
the Expiration Date (as defined below) ___________________ fully paid and
nonassessable shares of Common Stock (as defined below) (the “Warrant
Shares”).  Except as otherwise defined herein, capitalized
terms in this Warrant shall have the meanings set forth in Section
14.  This Warrant is one of a series of warrants to purchase shares of
Common Stock (the “SPA
Warrants” issued pursuant to those certain Purchase Agreements, dated as
of January __, 2010 (the “Subscription Date”), by and
among the Company and the investors (the “Investors”) referred to
therein (the “Purchase
Agreements”) pursuant to the Company’s Registration Statement on Form S-3
(No. 333-140373).

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    1.           EXERCISE OF
WARRANT.

     

    (a)             Mechanics of
Exercise.  Subject to the terms and conditions hereof
(including, without limitation, the limitations set forth in Section 1(c)), this
Warrant may be exercised by the Holder on any day on or after the Issuance Date,
in whole or in part (but not as to fractional shares), by (i) delivery of a
written notice, in the form attached hereto as Exhibit A (the “Exercise Notice”), of the
Holder’s election to exercise this Warrant and (ii) (A) payment to the
Company of an amount equal to the applicable Exercise Price multiplied by the
number of Warrant Shares as to which this Warrant is being exercised (the “Aggregate Exercise Price”) in
cash or wire transfer of immediately available funds or (B) by notifying the
Company that this Warrant is being exercised pursuant to a Cashless Exercise (as
defined in Section 1(d)).  The Holder shall not be required to
surrender this Warrant in order to effect an exercise hereunder, provided that
this Warrant is surrendered to the Company by the second Business Day following
the date on which the Company has received each of the Exercise Notice and the
Aggregate Exercise Price (the “Exercise Delivery Documents”).  On or
before the first Business Day following the date on which the Company has
received each of the Exercise Notice and the Aggregate Exercise Price (or notice
of a Cashless Exercise) (the “Exercise Delivery Documents”),
the Company shall transmit by facsimile or electronic mail an acknowledgment of
confirmation of receipt of the Exercise Delivery Documents to the Holder and the
Company’s transfer agent (the “Transfer
Agent”).  The Company shall deliver any objection to the
Exercise Delivery Documents on or before the second Business Day following the
date on which the Company has received all of the Exercise Delivery
Documents.  In the event of any discrepancy or dispute, the records of
the Company shall be controlling and determinative in the absence of manifest
error.  On or before the third Business Day following the date on
which the Company has received all of the Exercise Delivery Documents and after
the Company has received this Warrant (the “Share Delivery Date”), the
Company shall, (X) provided that the Transfer Agent is participating in The
Depository Trust Company (“DTC”) Fast Automated
Securities Transfer Program (the “FAST Program”) and so long as
the certificates therefor are not required to bear a legend regarding
restriction on transferability, upon the request of the Holder, credit such
aggregate number of shares of Common Stock to which the Holder is entitled
pursuant to such exercise to the Holder’s or its designee’s balance account with
DTC through its Deposit Withdrawal Agent Commission system, or (Y), if the
Transfer Agent is not participating in the FAST Program or if the certificates
are required to bear a legend regarding restriction on transferability, issue
and dispatch by overnight courier to the address as specified in the Exercise
Notice, a certificate, registered in the Company’s share register in the name of
the Holder or its designee, for the number of shares of Common Stock to which
the Holder is entitled pursuant to such exercise.  Upon delivery of
the Exercise Delivery Documents and surrender of this Warrant, the Holder shall
be deemed for all corporate purposes to have become the holder of record of the
Warrant Shares with respect to which this Warrant has been exercised,
irrespective of the date such Warrant Shares are credited to the Holder’s DTC
account or the date of delivery of the certificates evidencing such Warrant
Shares, as the case may be.  If this Warrant is submitted in
connection with any exercise pursuant to this Section 1(a) and the number of
Warrant Shares represented by this Warrant submitted for exercise is greater
than the number of Warrant Shares being acquired upon an exercise, then the
Company shall as soon as practicable and in no event later than five Business
Days after any exercise and at its own expense, issue a new Warrant (in
accordance with Section 7(d)) representing the right to purchase the number of
Warrant Shares purchasable immediately prior to such exercise under this
Warrant, less the number of Warrant Shares with respect to which this Warrant is
exercised.  The Company shall pay any and all taxes that may be
payable with respect to the issuance and delivery of Warrant Shares upon
exercise of this Warrant.

     

    (b)             Exercise
Price.  For purposes of this Warrant, “Exercise Price” means $2.75
per share of Common Stock, subject to adjustment as provided
herein.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    (c)             Limitations on
Exercises.  (1)  The Company shall not effect the
exercise of this Warrant, and the Holder shall not have the right to exercise
this Warrant, to the extent that after giving effect to such exercise, such
Person (together with such Person’s affiliates) would beneficially own in excess
of 4.99% (the “Maximum
Percentage”) of the shares of Common Stock outstanding immediately after
giving effect to such exercise.  For purposes of the foregoing
sentence, the aggregate number of shares of Common Stock beneficially owned by
such Person and its affiliates shall include the number of shares of Common
Stock issuable upon exercise of this Warrant with respect to which the
determination of such sentence is being made, but shall exclude shares of Common
Stock which would be issuable upon (i) exercise of the remaining, unexercised
portion of this Warrant beneficially owned by such Person and its affiliates and
(ii) exercise or conversion of the unexercised or unconverted portion of any
other securities of the Company beneficially owned by such Person and its
affiliates (including, without limitation, any convertible notes or convertible
preferred stock or warrants) subject to a limitation on conversion or exercise
analogous to the limitation contained herein.  Except as set forth in
the preceding sentence, for purposes of this paragraph, beneficial ownership
shall be calculated in accordance with Section 13(d) of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”).  For
purposes of this Warrant, in determining the number of outstanding shares of
Common Stock, the Holder may rely on the number of outstanding shares of Common
Stock as reflected in (1) the Company’s most recent Form 10-K, Form 10-Q,
Current Report on Form 8-K or other public filing with the Securities and
Exchange Commission, as the case may be, (2) a more recent public announcement
by the Company or (3) any other notice by the Company or the Transfer Agent
setting forth the number of shares of Common Stock outstanding.  For
any reason at any time, upon the written or oral request of the Holder, where
such request indicates that it is being made pursuant to this Warrant, the
Company shall within two Business Days confirm orally and in writing to the
Holder the number of shares of Common Stock then outstanding.  In any
case, the number of outstanding shares of Common Stock shall be determined after
giving effect to the conversion or exercise of securities of the Company,
including the SPA Warrants, by the Holder and its affiliates since the date as
of which such number of outstanding shares of Common Stock was
reported.  By written notice to the Company, the Holder may increase
or decrease the Maximum Percentage to any other percentage not in excess of
9.99% specified in such notice; provided, that (i)
any such increase will not be effective until the 61st day
after such notice is delivered to the Company and (ii) any such increase or
decrease will apply only to the Holder and not to any other holder of SPA
Warrants.

     

    (2)           No Exercise That Triggers
Pill.  This Warrant may not be exercised to acquire Warrant
Shares to the extent that when added to those already beneficially owned by the
Holder for purposes of the Rights Agreement dated as of September 7, 2001
between the Company and American Stock Transfer & Trust Company (the “Rights Agreement”), such
Warrant Shares would cause such Holder to become an Acquiring Person as that
term is used in the Rights Agreement with respect to that Holder.

     

    (d)             Cashless Exercise.
 The Holder may, in
its sole discretion, but only at times a registration statement covering the
issuance by the Company of the shares to be issued upon exercise of this Warrant
is not effective or an exemption from registration is not available, exercise this Warrant in
whole or in part and, in lieu of making the cash payment otherwise contemplated
to be made to the Company upon such exercise in payment of the Aggregate
Exercise Price, elect instead to receive upon such exercise the “Net Number” of
shares of Common Stock determined according to the following formula (a “Cashless
Exercise”):

     

    Net Number = (A x B) - (A x
C)

       
B

     

    For purposes of the foregoing
formula:

     

    A= the
total number of shares with respect to which this Warrant is then being
exercised.

     

    B= the
Weighted Average Price of the shares of Common Stock (as reported by Bloomberg)
for the five consecutive Trading Days ending on the date immediately preceding
the date of the Exercise Notice.

     

    C= the
Exercise Price then in effect for the applicable Warrant Shares at the time of
such exercise.

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    (e)             Disputes.  In
the case of a dispute as to the determination of the Exercise Price or the
arithmetic calculation of the Warrant Shares, the Company shall promptly issue
to the Holder the number of Warrant Shares that are not disputed and resolve
such dispute in accordance with Section 12.

     

    2.           ADJUSTMENT OF EXERCISE PRICE
AND NUMBER OF WARRANT SHARES.  The Exercise Price and the
number of Warrant Shares shall be adjusted from time to time as
follows:

     

    (a)             Adjustment upon Subdivision
or Combination of shares of Common Stock.  If the Company at
any time on or after the Subscription Date subdivides (by any stock split, stock
dividend, recapitalization or otherwise) one or more classes of its outstanding
shares of Common Stock into a greater number of shares, the Exercise Price in
effect immediately prior to such subdivision will be proportionately reduced and
the number of Warrant Shares will be proportionately increased.  If
the Company at any time on or after the Subscription Date combines (by
combination, reverse stock split or otherwise) one or more classes of its
outstanding shares of Common Stock into a smaller number of shares, the Exercise
Price in effect immediately prior to such combination will be proportionately
increased and the number of Warrant Shares will be proportionately
decreased.  Any adjustment under this Section 2(a) shall become
effective at the close of business on the date the subdivision or combination
becomes effective.

     

    (b)             Other
Events.  If any event occurs of the type contemplated by the
provisions of Section 2(a) but not expressly provided for by such provisions
(including, without limitation, the granting of stock appreciation rights,
phantom stock rights or other rights with equity features to the holders of the
Company’s equity securities), then the Company’s Board of Directors will make an
appropriate adjustment in the Exercise Price and the number of Warrant Shares so
as to protect the rights of the Holder; provided, that no
such adjustment pursuant to this Section 2(b) will increase the Exercise Price
or decrease the number of Warrant Shares as otherwise determined pursuant to
this Section 2.

     

    3.           RIGHTS UPON DISTRIBUTION OF
ASSETS.  If the Company shall declare or make any dividend or
other distribution of its assets (or rights to acquire its assets) in respect of
its Common Stock, by way of return of capital or otherwise (including, without
limitation, any distribution of cash, stock or other securities, property or
options by way of a dividend, spin off, reclassification, corporate
rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time
after the issuance of this Warrant, then, in each such case:

     

    (a)             any
Exercise Price in effect immediately prior to the close of business on the
record date fixed for the determination of holders of shares of Common Stock
entitled to receive the Distribution shall be reduced, effective as of the close
of business on such record date, to a price determined by multiplying such
Exercise Price by a fraction of which (i) the numerator shall be the Weighted
Average Price of the shares of Common Stock on the Trading Day immediately
preceding such record date minus the value of the Distribution (as determined in
good faith by the Company’s Board of Directors) applicable to one share of
Common Stock, and (ii) the denominator shall be the Weighted Average Price of
the shares of Common Stock on the Trading Day immediately preceding such record
date; and

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    (b)             the
number of Warrant Shares shall be increased to a number of shares equal to the
number of shares of Common Stock obtainable immediately prior to the close of
business on the record date fixed for the determination of holders of shares of
Common Stock entitled to receive the Distribution multiplied by the reciprocal
of the fraction set forth in the immediately preceding paragraph (a); provided, that in the
event that the Distribution is of shares of Common Stock or common stock of a
company whose common shares are traded on a national securities exchange or a
national automated quotation system (“Other Shares of Common
Stock”), then the Holder may elect to receive a warrant to purchase Other
Shares of Common Stock in lieu of an increase in the number of Warrant Shares,
the terms of which shall be identical to those of this Warrant, except that such
warrant shall be exercisable into the number of shares of Other Shares of Common
Stock that would have been payable to the Holder pursuant to the Distribution
had the Holder exercised this Warrant immediately prior to such record date and
with an aggregate exercise price equal to the product of the amount by which the
exercise price of this Warrant was decreased with respect to the Distribution
pursuant to the terms of the immediately preceding paragraph (a) and the number
of Warrant Shares calculated in accordance with the first part of this paragraph
(b).

     

    4.           PURCHASE RIGHTS; FUNDAMENTAL
TRANSACTIONS.

     

    (a)             Purchase
Rights.  In addition to any adjustments pursuant to Section 2
above, if at any time prior to the Expiration Date the Company grants, issues or
sells any Options, Convertible Securities or rights to purchase stock, warrants,
securities or other property pro rata to the record holders of any class of
shares of Common Stock (the “Purchase Rights”), then the
Holder will be entitled to acquire, upon the terms applicable to such Purchase
Rights, the aggregate Purchase Rights which the Holder could have acquired if
the Holder had held the number of shares of Common Stock acquirable upon
complete exercise of this Warrant (without regard to any limitations on the
exercise of this Warrant) immediately before the date on which a record is taken
for the grant, issuance or sale of such Purchase Rights, or, if no such record
is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase
Rights.

     

    (b)           Fundamental
Transactions.  Upon the occurrence of any Fundamental
Transaction, the Successor Entity shall succeed to, and be substituted for (so
that from and after the date of such Fundamental Transaction, the provisions of
this Warrant referring to the “Company” shall refer instead to the Successor
Entity), and may exercise every right and power of the Company and shall assume
all of the obligations of the Company under this Warrant with the same effect as
if such Successor Entity had been named as the Company herein.  Upon
consummation of the Fundamental Transaction, the Successor Entity shall deliver
to the Holder confirmation that there shall be issued upon exercise of this
Warrant at any time after the consummation of the Fundamental Transaction, in
lieu of the shares of the Common Stock (or other securities, cash, assets or
other property purchasable upon the exercise of the Warrant prior to such
Fundamental Transaction), such shares of stock, securities, cash, assets or any
other property whatsoever (including warrants or other purchase or subscription
rights) which the Holder would have been entitled to receive upon the happening
of such Fundamental Transaction had this Warrant been converted immediately
prior to such Fundamental Transaction, as adjusted in accordance with the
provisions of this Warrant.  In addition to and not in substitution
for any other rights hereunder, prior to the consummation of any Fundamental
Transaction pursuant to which holders of shares of Common Stock are entitled to
receive securities or other assets with respect to or in exchange for shares of
Common Stock (a “Corporate
Event”), the Company shall make appropriate provision to insure that the
Holder will thereafter have the right to receive upon an exercise of this
Warrant within 90 days after the consummation of the Fundamental Transaction
but, in any event, prior to the Expiration Date, in lieu of the shares of the
Common Stock (or other securities, cash, assets or other property) purchasable
upon the exercise of the Warrant prior to such Fundamental Transaction, such
shares of stock, securities, cash, assets or any other property whatsoever
(including warrants or other purchase or subscription rights) which the Holder
would have been entitled to receive upon the happening of such Fundamental
Transaction had the Warrant been exercised immediately prior to such Fundamental
Transaction.  Provision made pursuant to the preceding sentence shall
be in a form and substance reasonably satisfactory to the Required
Holders.  The provisions of this Section shall apply similarly and
equally to successive Fundamental Transactions and Corporate Events and shall be
applied without regard to any limitations on the exercise of this
Warrant.

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

    5.           NONCIRCUMVENTION.  The
Company hereby covenants and agrees that the Company will not, by amendment of
its Certificate of Incorporation, Bylaws or through any reorganization, transfer
of assets, consolidation, merger, scheme of arrangement, dissolution, issue or
sale of securities or any other voluntary action, avoid or seek to avoid the
observance or performance of any of the terms of this Warrant, and will at all
times in good faith carry out all the provisions of this Warrant and take all
action as may be required to protect the rights of the
Holder.  Without limiting the generality of the foregoing, the Company
(i) shall not increase the par value of any shares of Common Stock
receivable upon the exercise of this Warrant above the Exercise Price then in
effect, (ii) shall take all such actions as may be necessary or appropriate
in order that the Company may validly and legally issue fully paid and
nonassessable shares of Common Stock upon the exercise of this Warrant and (iii)
shall, so long as any of the SPA Warrants are outstanding, take all action
necessary to reserve and keep available out of its authorized and unissued
shares of Common Stock, solely for the purpose of effecting the exercise of the
SPA Warrants, the number of shares of Common Stock as shall from time to time be
necessary to effect the exercise of the SPA Warrants then outstanding (without
regard to any limitations on exercise).

     

    6.           WARRANT HOLDER NOT DEEMED A
STOCKHOLDER.  Except as otherwise specifically provided herein,
the Holder, solely in such Person’s capacity as a holder of this Warrant, shall
not be entitled to vote or receive dividends or be deemed the holder of share
capital of the Company for any purpose, nor shall anything contained in this
Warrant be construed to confer upon the Holder, solely in such Person’s capacity
as the Holder of this Warrant, any of the rights of a stockholder of the Company
or any right to vote, give or withhold consent to any corporate action (whether
any reorganization, issue of stock, reclassification of stock, consolidation,
merger, conveyance or otherwise), receive notice of meetings, receive dividends
or subscription rights, or otherwise, prior to the issuance to the Holder of the
Warrant Shares which such Person is then entitled to receive upon the due
exercise of this Warrant.  In addition, nothing contained in this
Warrant shall be construed as imposing any liabilities on the Holder to purchase
any securities (upon exercise of this Warrant or otherwise) or as a stockholder
of the Company, whether such liabilities are asserted by the Company or by
creditors of the Company.

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

    7.           REISSUANCE OF
WARRANTS.

     

    (a)             Transfer of
Warrant.  This Warrant may be offered for sale, sold,
transferred or assigned without the consent of the Company, except as may
otherwise be required by applicable securities laws.  Subject to
applicable securities laws, if this Warrant is to be transferred, the Holder
shall surrender this Warrant to the Company together with all applicable
transfer taxes, whereupon the Company will forthwith issue and deliver upon the
order of the Holder a new Warrant (in accordance with Section 7(d)), registered
as the Holder may request, representing the right to purchase the number of
Warrant Shares being transferred by the Holder and, if less then the total
number of Warrant Shares then underlying this Warrant is being transferred, a
new Warrant (in accordance with Section 7(d)) to the Holder representing the
right to purchase the number of Warrant Shares not being
transferred.

     

    (b)             Lost, Stolen or Mutilated
Warrant.  Upon receipt by the Company of evidence reasonably
satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant, and, in the case of loss, theft or destruction, of any
indemnification undertaking by the Holder to the Company in customary form or
the provision of reasonable security by the Holder to the Company and, in the
case of mutilation, upon surrender and cancellation of this Warrant, the Company
shall execute and deliver to the Holder a new Warrant (in accordance with
Section 7(d)) representing the right to purchase the Warrant Shares then
underlying this Warrant.

     

    (c)             Exchangeable for Multiple
Warrants.  This Warrant is exchangeable, upon the surrender
hereof by the Holder at the principal office of the Company together with all
applicable transfer taxes, for a new Warrant or Warrants (in accordance with
Section 7(d)) representing in the aggregate the right to purchase the number of
Warrant Shares then underlying this Warrant, and each such new Warrant will
represent the right to purchase such portion of such Warrant Shares as is
designated by the Holder at the time of such surrender; provided, however, that the
Company shall not be required to issue Warrants for fractional shares of Common
Stock hereunder.

     

    (d)             Issuance of New
Warrants.  Whenever the Company is required to issue a new
Warrant pursuant to the terms of this Warrant, such new Warrant shall (i) be of
like tenor with this Warrant, (ii) represent, as indicated on the face of such
new Warrant, the right to purchase the Warrant Shares then underlying this
Warrant (or in the case of a new Warrant being issued pursuant to Section 7(a)
or Section 7(c), the Warrant Shares designated by the Holder which, when added
to the number of shares of Common Stock underlying the other new Warrants issued
in connection with such issuance, does not exceed the number of Warrant Shares
then underlying this Warrant), (iii) have an issuance date, as indicated on the
face of such new Warrant which is the same as the Issuance Date and (iv) have
the same rights and conditions as this Warrant.

     

    8.           NOTICES.  Whenever
notice is required to be given under this Warrant, unless otherwise provided
herein, such notice shall be given in accordance with Section 6 of Annex I of
the Purchase Agreements.  The Company shall provide the Holder with
prompt written notice of all actions taken pursuant to this Warrant, including,
in reasonable detail, a description of such action and the reason or reasons
therefore.  Without limiting the generality of the foregoing, the
Company will give written notice to the Holder (i) immediately upon any
adjustment of the Exercise Price, setting forth in reasonable detail, and
certifying, the calculation of such adjustment and (ii) at least 10 days prior
to the date on which the Company closes its books or takes a record (A) with
respect to any dividend or distribution upon the shares of Common Stock, (B)
with respect to any grants, issuances or sales of any Options, Convertible
Securities or rights to purchase stock, warrants, securities or other property
pro rata to holders of shares of Common Stock or (C) for determining rights to
vote with respect to any Fundamental Transaction, dissolution or liquidation;
provided, that
in each case, such information shall be made known to the public prior to or in
conjunction with such notice being provided to the Holder.

    
      
         

      

      
        7

        
          

        

      

      
         

      

    

    9.           AMENDMENT AND
WAIVER.  Except as otherwise provided herein, the provisions of
this Warrant may be amended and the Company may take any action herein
prohibited, or omit to perform any act herein required to be performed by it,
only if the Company has obtained the written consent of the Required Holders;
provided, that
no such action may increase the exercise price of any SPA Warrant or decrease
the number of shares or class of stock obtainable upon exercise of any SPA
Warrant without the written consent of the Holder. No such amendment shall be
effective to the extent that it applies to less than all of the holders of the
SPA Warrants then outstanding.

     

    10.         GOVERNING
LAW.  This Warrant shall be governed by and construed and
enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Warrant shall be governed by,
the internal laws of the State of New York, without giving effect to any choice
of law or conflict of law provision or rule (whether of the State of New York or
any other jurisdictions) that would cause the application of the laws of any
jurisdictions other than the State of New York.

     

    11.         CONSTRUCTION;
HEADINGS.  This Warrant shall be deemed to be jointly drafted
by the Company and all of the Investors and shall not be construed against any
person as the drafter hereof.  The headings of this Warrant are for
convenience of reference and shall not form part of, or affect the
interpretation of, this Warrant.

     

    12.         DISPUTE
RESOLUTION.  In the case of a dispute as to the determination
of the Exercise Price or the arithmetic calculation of the Warrant Shares, the
Company shall submit the disputed determinations or arithmetic calculations via
facsimile within two Business Days of receipt of the Exercise Notice giving rise
to such dispute, as the case may be, to the Holder.  If the Holder and
the Company are unable to agree upon such determination or calculation of the
Exercise Price or the Warrant Shares within five Business Days of such disputed
determination or arithmetic calculation being submitted to the Holder, then the
Company shall, within two Business Days submit via facsimile (a) the disputed
determination of the Exercise Price to an independent, reputable investment bank
selected by the Company and approved by the Holder or (b) the disputed
arithmetic calculation of the Warrant Shares to the Company’s independent,
outside accountant.  The Company shall cause the investment bank or
the accountant, as the case may be, to perform the determinations or
calculations and notify the Company and the Holder of the results no later than
10 Business Days from the time it receives the disputed determinations or
calculations.  Such investment bank’s or accountant’s determination or
calculation, as the case may be, shall be binding upon all parties absent
demonstrable error.  The expenses of the investment bank and
accountant will be borne by the Company unless the investment bank or accountant
determines that the determination of the Exercise Price or the arithmetic
calculation of the Warrant Shares by the Holder was incorrect, in which case the
expenses of the investment bank and accountant will be borne by the
Holder.

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

    13.           REMEDIES, OTHER OBLIGATIONS,
BREACHES AND INJUNCTIVE RELIEF.  The remedies provided in this
Warrant shall be cumulative and in addition to all other remedies available
under this Warrant and the other Transaction Documents, at law or in equity
(including a decree of specific performance and/or other injunctive relief), and
nothing herein shall limit the right of the Holder to pursue actual damages for
any failure by the Company to comply with the terms of this
Warrant.  The Company acknowledges that a breach by it of its
obligations hereunder may cause irreparable harm to the Holder and that the
remedy at law for any such breach may be inadequate.  The Company
therefore agrees that, in the event of any such breach or threatened breach, the
holder of this Warrant shall be entitled, in addition to all other available
remedies, to seek an injunction restraining any
breach.  Notwithstanding the foregoing, the absence of an effective
registration statement relating to the issuance of Warrant Shares upon exercise
of the Warrant shall not provide the Holder with the right to net-settle this
Warrant in cash.  Furthermore, the absence of an effective
registration statement or applicable exemption from registration does not
alleviate the Company’s obligation to deliver the Warrant Shares upon exercise
of this Warrant.

     

    14.           CERTAIN
DEFINITIONS.  For purposes of this Warrant, the following terms
shall have the following meanings:

     

    (a)             “Bloomberg” means Bloomberg
Financial Markets.

     

    (b)             “Business Day” means any day
other than Saturday, Sunday or other day on which commercial banks in The City
of New York are authorized or required by law to remain closed.

     

    (c)             “Closing Bid Price” means, for
any security as of any date, the last closing bid price for such security on the
Principal Market, as reported by Bloomberg, or, if the Principal Market begins
to operate on an extended hours basis and does not designate the closing bid
price, then the last bid price of such security prior to 4:00:00 p.m., New York
Time, as reported by Bloomberg, or, if the Principal Market is not the principal
securities exchange or trading market for such security, the last closing bid
price or last trade price, respectively, of such security on the principal
securities exchange or trading market where such security is listed or traded as
reported by Bloomberg, or if the foregoing do not apply, the average of the bid
prices, or the ask prices, respectively, of any market makers for such security
as reported in the “pink sheets” by Pink Sheets LLC (formerly the National
Quotation Bureau, Inc.).  If the Closing Bid Price cannot be
calculated for a security on a particular date on any of the foregoing bases,
the Closing Bid Price of such security on such date shall be the fair market
value as mutually determined by the Company and the Holder.  If the
Company and the Holder are unable to agree upon the fair market value of such
security, then such dispute shall be resolved pursuant to Section
12.  All such determinations to be appropriately adjusted for any
stock dividend, stock split, stock combination or other similar transaction
during the applicable calculation period.

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

    (d)             “Common Stock” means
(i) the Company’s shares of Common Stock, $0.001 par value per share, and
(ii) any share capital into which such Common Stock shall have been changed
or any share capital resulting from a reclassification of such Common
Stock.

     

    (e)             “Convertible Securities” means
any stock or securities (other than Options) directly or indirectly convertible
into or exercisable or exchangeable for shares of Common Stock.

     

    (f)             “Eligible Market” means the
Principal Market, the NYSE Amex, The New York Stock Exchange, Inc., The NASDAQ
Global Select Market, The NASDAQ Capital Market, or the OTC Bulletin Board.®

     

    (g)             “Expiration Date” means the
fifth anniversary of the Issuance Date or, if such date falls on a day other
than a Business Day or on which trading does not take place on the Principal
Market (a “Holiday”),
the next date that is not a Holiday.

     

    (h)             “Fundamental Transaction” means
that the Company shall, directly or indirectly, in one or more related
transactions, (i) consolidate or merge with or into another Person, (ii) sell,
assign, transfer, convey or otherwise dispose of all or substantially all of the
properties or assets of the Company to another Person, (iii) allow another
Person to make a purchase, tender or exchange offer that is accepted by the
holders of more than the 50% of either the outstanding shares of Common Stock
(not including any shares of Common Stock held by the Person or Persons making
or party to, or associated or affiliated with the Persons making or party to,
such purchase, tender or exchange offer), (iv) consummate a stock purchase
agreement or other business combination (including, without limitation, a
reorganization, recapitalization, spin-off or scheme of arrangement) with
another Person whereby such other Person acquires more than the 50% of the
outstanding shares of Common Stock (not including any shares of Common Stock
held by the other Person or other Persons making or party to, or associated or
affiliated with the other Persons making or party to, such stock purchase
agreement or other business combination), (v) reorganize, recapitalize or
reclassify its Common Stock or (vi) any “person” or “group” (as these terms are
used for purposes of Sections 13(d) and 14(d) of the Exchange Act) is or shall
become the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act),
directly or indirectly, of 50% of the aggregate ordinary voting power
represented by issued and outstanding Common Stock.

     

    (i)             “Options” means any rights,
warrants or options to subscribe for or purchase shares of Common Stock or
Convertible Securities.

     

    (j)             “Parent Entity” of a Person
means an entity that, directly or indirectly, controls the applicable Person and
whose common stock or equivalent equity security is quoted or listed on an
Eligible Market, or, if there is more than one such Person or Parent Entity, the
Person or Parent Entity with the largest public market capitalization as of the
date of consummation of the Fundamental Transaction.

     

    (k)             “Person” means an individual, a
limited liability company, a partnership, a joint venture, a corporation, a
trust, an unincorporated organization, any other entity and a government or any
department or agency thereof.

     

    (l)             “Principal Market” means The
NASDAQ Global Market.

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

    (m)             “Required Holders” means the
holders of the SPA Warrants representing at least a majority of shares of Common
Stock underlying the SPA Warrants then outstanding.

     

    (n)             “Successor Entity” means the
Person (or, if so elected by the Required Holders, the Parent Entity) formed by,
resulting from or surviving any Fundamental Transaction or the Person (or, if so
elected by the Required Holders, the Parent Entity) with which such Fundamental
Transaction shall have been entered into.

     

    (o)             “Trading Day” means any day on
which the Common Stock is traded on the Principal Market, or, if the Principal
Market is not the principal trading market for the Common Stock, then on the
principal securities exchange or securities market on which the Common Stock is
then traded; provided that “Trading Day” shall not include any day on which the
Common Stock is scheduled to trade on such exchange or market for less than 4.5
hours or any day that the Common Stock is suspended from trading during the
final hour of trading on such exchange or market (or if such exchange or market
does not designate in advance the closing time of trading on such exchange or
market, then during the hour ending at 4:00:00 p.m., New York
Time).

     

    (p)             “Weighted Average Price” means,
for any security as of any date, the dollar volume-weighted average price for
such security on the Principal Market during the period beginning at 9:30:01
a.m., New York City time, and ending at 4:00:00 p.m., New York City time, as
reported by Bloomberg through its “Volume at Price” function or, if the
foregoing does not apply, the dollar volume-weighted average price of such
security in the over-the-counter market on the electronic bulletin board for
such security during the period beginning at 9:30:01 a.m., New York City time,
and ending at 4:00:00 p.m., New York City time, as reported by Bloomberg, or, if
no dollar volume-weighted average price is reported for such security by
Bloomberg for such hours, the average of the highest closing bid price and the
lowest closing ask price of any of the market makers for such security as
reported in the “pink sheets” by Pink Sheets LLC.  If the Weighted
Average Price cannot be calculated for such security on such date on any of the
foregoing bases, the Weighted Average Price of such security on such date shall
be the fair market value as mutually determined by the Company and the Required
Holders.  If the Company and the Required Holders are unable to agree
upon the fair market value of such security, then such dispute shall be resolved
pursuant to Section 12 with the term “Weighted Average Price” being substituted
for the term “Exercise Price.”  All such determinations shall be
appropriately adjusted for any share dividend, share split or other similar
transaction during such period.

     

    [Signature
Page Follows]

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

    IN WITNESS WHEREOF, the
Company has caused this Warrant to Purchase Common Stock to be duly executed as
of the Issuance Date set out above.

    

    
      
        
          
            	 
      	
                    GENVEC,
      INC.

                  
	 
      	 
      	 
      
	 
      	
                    By:

                  	 
      
	 
      	 
      	
                    Name:

                  	
                    Douglas
      J. Swirsky

                  
	 
      	 
      	
                    Title:

                  	
                    Senior
      Vice President, Chief Financial Officer, Treasurer and Corporate
      Secretary

                  

          

        

      

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    EXHIBIT
A

    

    EXERCISE
NOTICE

     

    TO
BE EXECUTED BY THE REGISTERED HOLDER TO EXERCISE THIS

    WARRANT
TO PURCHASE COMMON STOCK

    

    GENVEC,
INC.

     

    The
undersigned holder hereby exercises the right to purchase _________________ of
the shares of Common Stock (“Warrant Shares”) of GenVec,
Inc., a Delaware corporation (the “Company”), evidenced by the
attached Warrant to Purchase Common Stock (the “Warrant”).  Capitalized
terms used herein and not otherwise defined shall have the respective meanings
set forth in the Warrant.

    

    1.  Form of Exercise
Price.  The Holder intends that payment of the Exercise Price
shall be made as:

    

    
      
        
          
            	 
      	 
      	
                    ____________

                  	 
      	
                    a
      “Cash Exercise” with
      respect to _________________ Warrant Shares.

                  
	 
      	 
      	 
      	 
      	 
      
	 
      	
                      

                  	
                    ____________

                  	
                      

                  	
                    a
      “Cashless Exercise” with
      respect to _______________ Warrant
Shares.

                  

          

        

      

    

    

    2.  Payment of Exercise
Price.  In the event that the holder has elected a Cash
Exercise with respect to some or all of the Warrant Shares to be issued pursuant
hereto, the holder shall pay the Aggregate Exercise Price in the sum of
$___________________ to the Company in accordance with the terms of the
Warrant.

    

    3.  Delivery of Warrant
Shares.  The Company shall deliver to the holder __________
Warrant Shares in accordance with the terms of the Warrant.

    

    4.  Representations and
Warranties.  By its delivery of this Exercise Notice, the
undersigned represents and warrants to the Company that in giving effect to the
exercise evidenced hereby the holder will not beneficially own in excess of the
number of shares of Common Stock (determined in accordance with Section 13(d) of
the Securities Exchange Act of 1934) permitted to be owned under Section 1(c) of
this Warrant to which this notice relates.

    

    Date:
_______________ __, ______

    

    
      
        
          	 
      	 
      
	
                  Name
      of Registered Holder

                	 
      
	 
      	 
      
	
                  By:

                	 
      	 
      
	 
      	
                  Name:

                	 
      
	 
      	
                  Title:

                	 
      

        

      

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    ACKNOWLEDGMENT

    

    The Company hereby acknowledges this
Exercise Notice.

    

    
      
        
          	 
      	
                  GENVEC,
      INC.

                
	 
      	 
      
	 
      	
                  By:

                	 
      
	 
      	 
      	
                  Name:

                	 
      
	 
      	 
      	
                  Title:January
27, 2010

    

    GenVec,
Inc.

    65 West
Watkins Mill Road

    Gaithersburg,
MD  20878

    

    Ladies
and Gentlemen:

    

    The
undersigned (the “Investor”) hereby confirms and agrees with you as
follows:

    

    1.           This
Purchase Agreement (the “Agreement”) is made as of the date hereof between
GenVec, Inc., a Delaware corporation (the “Company”), and the Investor that is a
signatory to this Agreement.

    

    2.           The
Company has authorized the sale and issuance of up to 14,000,000 shares of its
common stock (the “Offered Shares”), par value $0.001 per share (the “Common
Stock”), and warrants to purchase up to 4,200,000 shares of Common Stock (the
“Offered Warrants”) (the “Offering”).  The Offered Shares and the
Offered Warrants shall be sold together as units, each unit consisting of one
Offered Share and 0.30 of an Offered Warrant (the “Warrant”) to purchase one
share of Common Stock (such units are referred to herein individually as the
“Offered Security” and collectively as the “Offered Securities”).  The
exercise price of the Warrants is $2.75 per share.  The Offering is
being made pursuant to an effective shelf registration statement on Form S-3
(SEC File No. 333-140373).

    

    3.           The
Company and the Investor agree that the Offering is being made subject to the
execution by the Company and the Placement Agents of the Placement Agency
Agreement, delivery of a preliminary term sheet describing the proposed
offering, delivery of the base prospectus relating to the Offered Securities and
delivery of additional offering information, including pricing
information.  The Company and the Investor agree that the Investor
will purchase from the Company and the Company will issue and sell to the
Investor the number of Offered Securities set forth below the Investor’s name on
Schedule I hereto, at a purchase price of $2.00 per unit, pursuant to the Terms
and Conditions for Purchase of Offered Securities attached hereto as Annex I and
incorporated herein by reference as if fully set forth herein.  The
Investor acknowledges that the Offering is not being underwritten by the
Placement Agents and that there is no minimum offering amount.  Shares
of Common Stock will be credited to the Investor using customary book-entry
procedures.  The executed Warrant will be delivered pursuant to the
terms thereof.

    

    4.           The
Investor represents that, except as set forth below, (a) it has had no position,
office or other material relationship within the past three years with the
Company or persons known to it to be affiliates of the Company, (b) neither it,
nor any group of which it is a member or to which it is related, beneficially
owns (including the right to acquire or vote) more than 19.9% of any class of
securities of the Company and (c) it is not a FINRA member or a person
associated with any FINRA member as of the date hereof.

    

    5.           The
Investor confirms that it has had full access to all filings made by the Company
with the Securities and Exchange Commission, including the registration
statement and base prospectus relating to the Offered Securities, and the
documents incorporated by reference therein, and that it was able to read,
review, download and print each such filing.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    Please
confirm that the foregoing correctly sets forth the agreement between us by
signing in the space provided below for that purpose.

    

    
      
        
          
            
              
                
                  
                    
                      	 
      	
                              Name of Investor:

                            	 
      
	 	 	 	 
	 
      	 
      	
                              By:

                            	 
      
	 
      	 
      	 
      	 
      
	 
      	 
      	
                              Name:

                            	 
      
	 
      	 
      	 
      	 
      
	 
      	 
      	
                              Title:

                            	 
      

                    

                  

                

              

            

          

        

      

    

    

    
      
        
          
            
              	
                      AGREED
      AND ACCEPTED:

                    	 
      
	 
      	 
      	 
      
	
                      GENVEC,
      INC.

                    	 
      
	 
      	 
      	 
      
	
                      By:

                    	 
      	 
      
	 
      	 
      	 
      
	
                      Name:

                    	 
      	 
      
	 
      	 
      	 
      
	
                      Title:

                    	 
      	 
      

            

          

        

      

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    SCHEDULE
I

    

    SCHEDULE
OF INVESTORS

     

    
      
        
          
            
              
                
                  	 
      	
                          Name
      of Investor:

                        	 
      
	 
      	 
      	 
      
	 
      	 
      	 
      
	 
      	 
      	 
      
	 
      	
                          Name
      of Individual Representing Investor:

                        	 
      
	 
      	 
      	 
      
	 
      	 
      	 
      
	 
      	 
      	 
      
	 
      	
                          Title
      of Individual Representing Investor:

                        	 
      
	 
      	 
      	 
      
	 
      	 
      	 
      

                

              

            

          

        

      

    

     

    
      
        
          
            
              
                	 
      	
                        Address:

                      	 
      	 
      
	 
      	 
      	 
      	 
      
	 
      	
                        Telephone:

                      	 
      	 
      
	 
      	 
      	 
      	 
      
	 
      	
                        Telecopier:

                      	 
      	 
      

              

            

          

        

      

    

     

    
      
        
          
            
              
                
                  	
                          Number of Offered

                          Shares to Be

                          Purchased

                        	 	
                          Number of Offered

                          Warrants to Be

                          Purchased

                        	 	
                          Price Per Offered

                          Securities In

                          Dollars

                        	 	 	
                          Aggregate

                          Purchase Price

                        	 
	 	 	 	 
      	 	$	2.00	 	 	$	 	 

                

              

            

          

        

      

    

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    ANNEX
I

    

    TERMS
AND CONDITIONS FOR PURCHASE OF OFFERED SECURITIES

    

    1.           Agreement to Sell and
Purchase the Offered Securities; Placement Agents.

    

    1.1         Upon
the terms and subject to the conditions hereinafter set forth, at the Closing
(as defined in Section 2 below), the Company will sell to the Investor, and the
Investor will purchase from the Company, the number of shares of Common Stock
and the number of Warrants set forth on Schedule I of this Agreement below such
Investor’s name at the purchase price set forth therein.

    

    1.2         The
Company may enter into agreements similar to this Agreement with certain other
investors (the “Other Investors”) and expects to complete sales of Offered
Securities to them.  (The Investor and the Other Investors hereinafter
collectively are referred to as the “Investors,” and this Agreement and the
agreements executed by the Other Investors are hereinafter collectively referred
to as the “Agreements”). The Company may accept or reject any one or more
Agreements in its sole discretion.

    

    1.3         The
Company has entered into a Placement Agency Agreement (the “Placement Agency
Agreement”) dated the date hereof with Roth Capital Partners, LLC and Merriman
Curhan Ford & Co. in their capacities as Placement Agents for the Offering
(together, the “Placement Agents”), and the Company has agreed to pay the
Placement Agents a fee in respect of the sale of the Common Stock and
Warrants.

    

    2.           Delivery of the Shares at
Closing.  The completion of the purchase and sale of the
Offered Securities (the “Closing”) shall take place at a place and time (the
“Closing Date”) to be specified by the Company and the Placement Agents, in
accordance with Rule 15c6-1 promulgated under the Securities Exchange Act of
1934, as amended (the “Exchange Act”).

    

     
The Company’s obligation to issue and sell the Offered Securities at Closing to
the Investor shall be subject to the accuracy of the representations and
warranties made by the Investor and the fulfillment of those undertakings of the
Investor to be fulfilled prior to the Closing.

    

     
The Investor’s obligation to purchase the Offered Securities shall be subject to
the condition that the Placement Agents shall not have (a) terminated the
Placement Agency Agreement pursuant to the terms thereof or (b) determined that
the conditions to closing in the Placement Agency Agreement have not been
satisfied.

    

     At
the Closing, (i) the Investor shall remit by wire transfer the amount of funds
equal to the aggregate purchase price for the Units being purchased by the
Investor to an account designated by the Company (the “Purchase Price”) and (ii)
upon receipt of the Purchase Price, the Company shall (a) deliver the Offered
Shares purchased by the Investor to the Investor through DTC directly to the
account(s) of the applicable DTC Holder as set forth on Annex II and (b) deliver
the Warrants by mail or overnight carrier to the Investors at the address set
forth on Annex II.

    

    3.           Representations, Warranties
and Covenants of the Company.  The Company hereby represents
and warrants to, and covenants with, the Investor, as follows:

    

    3.1         The
issuance and sale of each of the Offered Shares and the Offered Warrants have
been duly authorized by the Company, and the Offered Shares, when issued and
paid for in accordance with this Agreement, will be duly and validly issued,
fully paid and nonassessable and will not be subject to preemptive or similar
rights.  The Warrant Shares have been duly authorized and reserved for
issuance pursuant to the terms of the Offered Warrants, and the Warrant Shares,
when issued by the Company upon valid exercise of the Offered Warrants and
payment of the exercise price, will be duly and validly issued, fully paid and
nonassessable and will not be subject to preemptive or similar
rights.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    3.2         Each
of this Agreement and the Warrants constitutes a valid and binding obligation of
the Company enforceable against the Company in accordance with its terms,
subject to the effect of applicable bankruptcy, insolvency or similar laws
affecting creditors’ rights generally and equitable principles of general
applicability.

    

    3.3         For
a period of 60 days from the date hereof, the Company shall not offer or sell
any equity or equity-related securities in any public or private offering to one
or more institutional investors without the Investor’s prior written consent,
which, for the sake of clarity, will not preclude the Company from, among other
things: (i) the offer or sale of the Offered Securities to the Investor as
contemplated hereby; (ii) the offer or sale of equity or equity-related
securities pursuant to benefit plans for the benefit of the Company’s officers,
directors, employees or consultants; (iii) the offer or sale of equity or
equity-related securities pursuant to any shareholder rights plan of the
Company; or (iv) the offer or sale of equity or equity-related securities as
part of a strategic collaboration, license, partnership, venture or similar
transaction.

    

    3.4         The
Company shall not effect any offer or sale of any equity or equity-related
securities that would result in the transactions contemplated hereby becoming
subject to stockholder approval under the rules and regulations of FINRA or the
NASDAQ Global Market.

    

    3.5         It
is understood and acknowledged by the Company that: (i) except pursuant to the
terms of this Agreement and any confidentiality agreement entered into by the
Investor with respect to the transactions contemplated hereby, the Investor has
not been asked by the Company to agree, nor has the Investor agreed, to desist
from purchasing or selling, long and/or short, securities of the Company, or
“derivative” securities based on securities issued by the Company or to hold the
Offered Securities for any specified term; (ii) past or future open market or
other transactions by the Investor, specifically including, without limitation,
Short Sales or “derivative” transactions, before or after the closing of this or
future private placement transactions, may negatively impact the market price of
the Company’s publicly-traded securities; (iii) the Investor, and
counter-parties in “derivative” transactions to which the Investor is a party,
directly or indirectly, presently may have a “short” position in the Common
Stock, and (iv) the Investor shall not be deemed to have any affiliation with or
control over any arm’s length counter-party in any “derivative” transaction
merely by reason of such “derivative” transaction.  The Company
further understands and acknowledges that (y) subject to the terms of this
Agreement and any confidentiality agreement entered into by the Investor with
respect to the transactions contemplated hereby, the Investor may engage in
hedging activities at various times during the period that the Offered
Securities are outstanding, including, without limitation, during the periods
that the value of the Warrant Shares deliverable with respect to Offered
Securities are being determined, and (z) such hedging activities (if any) could
reduce the value of the existing stockholders' equity interests in the Company
at and after the time that the hedging activities are being
conducted.

    

    3.6         The
Company will use its commercially reasonable efforts to maintain the
effectiveness of the registration statement in accordance with the rules and
regulations promulgated by the Securities and Exchange Commission.

    

    3.7         Prior
to 9:30 AM New York City time on January 27, 2010, the Company will issue a
press release (the “Press Release”) via BusinessWire (or other national wire
service) announcing the transaction contemplated by this
Agreement.  In connection with the transactions contemplated by this
Agreement, the Company has not disclosed, or caused to be disclosed, to the
Investor any material non-public information regarding the Company that will not
at the time of the issuance of the Press Release be in the public
domain.

    

    3.8         As
of the Closing Date, the Company shall have duly authorized and reserved for
issuance a number of shares of Common Stock which equals the number
of Offered Warrants.  The Company shall, so long as any of
the Offered Warrants are outstanding, take all action necessary to reserve
and keep available out of its authorized and unissued capital stock,
solely for the purpose of effecting the exercise of the Offered Warrants,
100% of the number of shares of Common Stock issuable upon exercise of the
Warrants.

    

    4.           Representations, Warranties
and Covenants of the Investor.  The Investor represents and
warrants to the Company as follows:

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    4.1         The
Investor has received the Company’s base prospectus relating to the Offered
Securities and the preliminary term sheet describing the terms of the proposed
Offering.  The Investor acknowledges that the Investor has received
certain additional information regarding the Offering, including pricing
information (the “Offering Information”). Such Offering Information may be
provided to the Investor by any means permitted under the Securities Act of
1933, as amended, including through a prospectus supplement, a free writing
prospectus and oral communications.

    

    4.2         The
Investor has full right, power, authority and capacity to enter into this
Agreement and to consummate the transactions contemplated hereby and has taken
all necessary action to authorize the execution, delivery and performance of
this Agreement, and this Agreement constitutes a valid and binding obligation of
the Investor enforceable against the Investor in accordance with its terms,
subject to the effect of applicable bankruptcy, insolvency or similar laws
affecting creditors’ rights generally and equitable principles of general
applicability.

    

    4.3         The
Investor is knowledgeable, sophisticated and experienced in making, and is
qualified to make, decisions with respect to investments in shares representing
an investment decision like that involved in the purchase of the Offered
Securities and has, in connection with its decision to purchase the number of
Offered Securities set forth on Schedule I to the Agreement, relied solely upon
the registration statement, the base prospectus, the preliminary term sheet, the
Offering Information and any amendments or supplements thereto and has not
relied upon any information provided by the Placement Agents.

    

    4.4         The
Investor understands that nothing in the registration statement, the base
prospectus, the preliminary term sheet, the Offering Information and any
amendments or supplements thereto, this Agreement or any other materials
presented to such Investor in connection with the purchase and sale of the
Offered Securities constitutes legal, tax or investment advice.  The
Investor has consulted such legal, tax and investment advisors as it, in its
sole discretion, has deemed necessary or appropriate in connection with its
purchase of Offered Securities.

    

    4.5           The
Investor will not, upon the Closing of the transactions contemplated by this
Agreement, beneficially own, as calculated in accordance with Section 13(d) of
the Securities Exchange Act of 1934, as amended, in excess of, 19.99% of the
shares of Common Stock outstanding.

    

    4.6         From
and after obtaining knowledge of the sale of the Offered Securities contemplated
hereby, the Investor has not engaged in any purchases or sales of the securities
of the Company (including, without limitation, any Short Sales (as defined
herein) involving the Company’s securities), and has not violated its
obligations of confidentiality.  The Investor covenants that it will not
engage in any purchases or sales of the securities of the Company (including
Short Sales) or disclose any information about the contemplated offering (other
than to its advisors that are under a legal obligation of confidentiality) prior
to the time that the transactions contemplated by this Agreement are publicly
disclosed.  The Investor agrees that it will not use any of the Units
acquired pursuant to this Agreement to cover any short position in the Common
Stock if doing so would be in violation of applicable securities laws.  For
purposes hereof, “Short Sales” include, without limitation, all “short sales” as
defined in Rule 200 promulgated under Regulation SHO under the Exchange Act,
whether or not against the box, and all types of direct and indirect stock
pledges, forward sales contracts, options, puts, calls, short sales, swaps, “put
equivalent positions” (as defined in Rule 16a-1(h) under the Exchange Act) and
similar arrangements (including on a total return basis), and sales and other
transactions through non-US broker dealers or foreign regulated
brokers.

     

    5.           Survival of Representations,
Warranties and Agreements.  Notwithstanding any investigation
made by any party to this Agreement, all covenants, agreements, representations
and warranties made by the Company and the Investor herein shall survive the
execution of this Agreement, the delivery to such Investor of the Offered
Securities being purchased and the payment therefor.

    

    6.           Notices.  All
notices, requests, consents and other communications hereunder shall be in
writing, shall be mailed (A) if within domestic United States, by first-class
registered or certified airmail, or nationally recognized overnight express
courier, postage prepaid, or by facsimile, or (B) if delivered from outside the
United States, by International Federal Express or facsimile, and shall be
deemed given (i) if delivered by first-class registered or certified mail
domestic, three business days after so mailed, (ii) if delivered by a nationally
recognized overnight carrier, one business day after so mailed, (iii) if
delivered by International Federal Express, two business days after so mailed,
(iv) if delivered by facsimile, upon electronic confirmation of receipt and
shall be delivered as addressed as follows: (a) if to the Company, at the office
of the Company, 65 West Watkins Mill Road, Gaithersburg, MD  20878,
Attention: Douglas J. Swirsky, with copies to Hogan & Hartson LLP, 100
International Drive, Suite 2000, Baltimore, MD  21202, Attention:
Asher M. Rubin, Esq.; and (b) if to an Investor, at its address on Schedule I
hereto, or at such other address or addresses as may have been furnished to the
Company in writing by such Investor.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    7.           Changes.  This
Agreement may not be modified or amended except pursuant to an instrument in
writing signed by the Company and the Investor.

    

    8.           Headings.  The
headings of the various sections of this Agreement have been inserted for
convenience or reference only and shall not be deemed to be part of this
Agreement.

    

    9.           Severability.  In
case any provision contained in this Agreement should be invalid, illegal or
unenforceable in any respect, the validity, legality and enforceability of the
remaining provisions contained herein shall not in any way be affected or
impaired thereby.

    

    10.         Governing
Law.  This Agreement shall be governed by, and construed in
accordance with, the internal laws of the State of New York, without giving
effect to the principles of conflicts of law.

    

    11.         Counterparts;
Facsimile.  This Agreement may be executed in two or more
counterparts, each of which shall constitute an original, but all of which, when
taken together, shall constitute one instrument, and shall become effective when
one or more counterparts have been signed by each party hereto and delivered to
the other parties.  Facsimile signatures shall be as effective as
original signatures.

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    Annex II

     

    GENVEC,
INC.

     

    INVESTOR
QUESTIONNAIRE

     

    Pursuant
to Annex I to
the Agreement, please provide us with the following information:

     

    
      
        
          
            
              
                
                  
                    
                      
                        	
                                1.
      The exact name that your Shares and Warrants are to be registered in. You
      may use a nominee name if appropriate:

                              	 
      	 
      
	 
      	 
      	 
      
	
                                2.
      The relationship between the Investor and the registered holder listed in
      response to item 1 above:

                              	 
      	 
      
	 
      	 
      	 
      
	
                                3.
      The mailing address of the registered holder listed in response to item 1
      above:

                              	 
      	 
      
	 
      	 
      	 
      
	
                                4.
      The Social Security Number or Tax Identification Number of the registered
      holder listed in the response to item 1 above:

                              	 
      	 
      
	 
      	 
      	 
      
	
                                5.
      Name of DTC Participant (broker-dealer at which the account or accounts to
      be credited with the Shares are maintained):

                              	 
      	 
      
	 
      	 
      	 
      
	
                                6.
      DTC Participant Number:

                              	 
      	 
      
	 
      	 
      	 
      
	
                                7.
      Name of Account at DTC Participant being credited with the
      Shares:

                              	 
      	 
      
	 
      	 
      	 
      
	
                                8.
      Account Number at DTC Participant being credited with the
      Shares:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00167-of-00352.parquet"}]]